Janssen Announces Submission to U.S. FDA for New DARZALEX Based Combination Regimen for Patients With Relapsed/Refractory Multiple Myeloma
February 11, 2020
February 11, 2020
RARITAN, New Jersey, Feb. 11 -- Johnson & Johnson issued the following news release:
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX(R) (daratumumab) in combination with Kyprolis(R) (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 C . . .
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX(R) (daratumumab) in combination with Kyprolis(R) (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 C . . .